MA30006B1 - Composes anti-hypercholesterolemiques - Google Patents
Composes anti-hypercholesterolemiquesInfo
- Publication number
- MA30006B1 MA30006B1 MA30894A MA30894A MA30006B1 MA 30006 B1 MA30006 B1 MA 30006B1 MA 30894 A MA30894 A MA 30894A MA 30894 A MA30894 A MA 30894A MA 30006 B1 MA30006 B1 MA 30006B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- cholesterol
- hypercholesterolemic compounds
- hypercholesterolemic
- esters
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000001906 cholesterol absorption Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention fournit des inhibiteurs de l'absorption du cholestérol de formule 1 et les sels pharmaceutiquement acceptables et esters de ceux-là. Les composés sont utiles pour abaisser les niveaux du cholestérol plasmatique, en particulier le LDL-cholestérol, et pour le traitement et la prévention de l'athérosclérose et des événements de la maladie athéroscléreuse.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72378105P | 2005-10-05 | 2005-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30006B1 true MA30006B1 (fr) | 2008-12-01 |
Family
ID=37845278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30894A MA30006B1 (fr) | 2005-10-05 | 2008-05-02 | Composes anti-hypercholesterolemiques |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090137546A1 (fr) |
| EP (1) | EP1934175B1 (fr) |
| JP (1) | JP4879991B2 (fr) |
| KR (1) | KR20080050610A (fr) |
| CN (1) | CN101277930A (fr) |
| AR (1) | AR058068A1 (fr) |
| AT (1) | ATE488495T1 (fr) |
| AU (1) | AU2006302584B2 (fr) |
| BR (1) | BRPI0616834A2 (fr) |
| CA (1) | CA2624481C (fr) |
| CR (1) | CR9903A (fr) |
| DE (1) | DE602006018341D1 (fr) |
| DO (1) | DOP2006000211A (fr) |
| EA (1) | EA200801008A1 (fr) |
| ES (1) | ES2354460T3 (fr) |
| GT (1) | GT200600444A (fr) |
| IL (1) | IL190434A0 (fr) |
| MA (1) | MA30006B1 (fr) |
| NO (1) | NO20082075L (fr) |
| PE (1) | PE20070493A1 (fr) |
| SV (1) | SV2009002863A (fr) |
| TN (1) | TNSN08153A1 (fr) |
| TW (1) | TW200806623A (fr) |
| WO (1) | WO2007044318A2 (fr) |
| ZA (1) | ZA200802587B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| JP2007516287A (ja) * | 2003-12-23 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| ATE485267T1 (de) * | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| AR057072A1 (es) * | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| CA2672221A1 (fr) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Compose anti-hypercholesterolemique |
| DE102009023046B4 (de) | 2008-05-30 | 2016-10-13 | Hyundai Motor Company | Automatisch schaltbares Getriebe eines Kraftfahrzeuges |
| WO2010056788A1 (fr) * | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Composés anti-hypercholestérolémiques |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU658441B2 (en) * | 1991-07-23 | 1995-04-13 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| WO1995035277A1 (fr) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Composes d'azetidinone substitues utilises comme agent hypercholesterolemiant |
| US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| IL156550A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| WO2004081002A1 (fr) * | 2003-03-07 | 2004-09-23 | Schering Corporation | Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie |
| JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| JP2007516287A (ja) * | 2003-12-23 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
| EP1851197A2 (fr) * | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Derives de phenylazetidinone |
| US7696177B2 (en) * | 2005-06-15 | 2010-04-13 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| KR20090091120A (ko) * | 2006-11-02 | 2009-08-26 | 사노피-아벤티스 도이칠란트 게엠베하 | 향상된 약리학적 특성을 갖는 피페라진-1-설폰산으로 치환된 신규한 디페닐아제티디논 |
-
2006
- 2006-09-26 TW TW095135631A patent/TW200806623A/zh unknown
- 2006-09-27 AR ARP060104231A patent/AR058068A1/es unknown
- 2006-09-29 JP JP2008534613A patent/JP4879991B2/ja not_active Expired - Fee Related
- 2006-09-29 AT AT06816084T patent/ATE488495T1/de not_active IP Right Cessation
- 2006-09-29 AU AU2006302584A patent/AU2006302584B2/en not_active Ceased
- 2006-09-29 ES ES06816084T patent/ES2354460T3/es active Active
- 2006-09-29 EA EA200801008A patent/EA200801008A1/ru unknown
- 2006-09-29 CN CNA2006800369359A patent/CN101277930A/zh active Pending
- 2006-09-29 BR BRPI0616834A patent/BRPI0616834A2/pt not_active IP Right Cessation
- 2006-09-29 DE DE602006018341T patent/DE602006018341D1/de active Active
- 2006-09-29 KR KR1020087008305A patent/KR20080050610A/ko not_active Withdrawn
- 2006-09-29 WO PCT/US2006/038551 patent/WO2007044318A2/fr not_active Ceased
- 2006-09-29 CA CA2624481A patent/CA2624481C/fr not_active Expired - Fee Related
- 2006-09-29 US US11/992,990 patent/US20090137546A1/en not_active Abandoned
- 2006-09-29 EP EP06816084A patent/EP1934175B1/fr active Active
- 2006-10-03 GT GT200600444A patent/GT200600444A/es unknown
- 2006-10-03 PE PE2006001201A patent/PE20070493A1/es not_active Application Discontinuation
- 2006-10-04 US US11/542,966 patent/US7704988B2/en not_active Expired - Fee Related
- 2006-10-05 DO DO2006000211A patent/DOP2006000211A/es unknown
-
2008
- 2008-03-20 ZA ZA200802587A patent/ZA200802587B/xx unknown
- 2008-03-25 IL IL190434A patent/IL190434A0/en unknown
- 2008-04-04 TN TNP2008000153A patent/TNSN08153A1/en unknown
- 2008-04-04 SV SV2008002863A patent/SV2009002863A/es not_active Application Discontinuation
- 2008-04-18 CR CR9903A patent/CR9903A/es not_active Application Discontinuation
- 2008-05-02 NO NO20082075A patent/NO20082075L/no not_active Application Discontinuation
- 2008-05-02 MA MA30894A patent/MA30006B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006302584B2 (en) | 2011-10-13 |
| KR20080050610A (ko) | 2008-06-09 |
| ES2354460T3 (es) | 2011-03-15 |
| US7704988B2 (en) | 2010-04-27 |
| JP2009511475A (ja) | 2009-03-19 |
| WO2007044318A2 (fr) | 2007-04-19 |
| CR9903A (es) | 2008-07-29 |
| US20070078098A1 (en) | 2007-04-05 |
| SV2009002863A (es) | 2009-02-19 |
| CN101277930A (zh) | 2008-10-01 |
| US20090137546A1 (en) | 2009-05-28 |
| JP4879991B2 (ja) | 2012-02-22 |
| ZA200802587B (en) | 2009-06-24 |
| DE602006018341D1 (de) | 2010-12-30 |
| NO20082075L (no) | 2008-07-04 |
| GT200600444A (es) | 2007-05-04 |
| IL190434A0 (en) | 2008-11-03 |
| ATE488495T1 (de) | 2010-12-15 |
| AR058068A1 (es) | 2008-01-23 |
| WO2007044318A3 (fr) | 2007-07-12 |
| PE20070493A1 (es) | 2007-06-13 |
| EA200801008A1 (ru) | 2009-02-27 |
| TW200806623A (en) | 2008-02-01 |
| BRPI0616834A2 (pt) | 2016-08-23 |
| CA2624481C (fr) | 2012-04-03 |
| CA2624481A1 (fr) | 2007-04-19 |
| AU2006302584A1 (en) | 2007-04-19 |
| EP1934175B1 (fr) | 2010-11-17 |
| EP1934175A2 (fr) | 2008-06-25 |
| TNSN08153A1 (en) | 2009-10-30 |
| DOP2006000211A (es) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08153A1 (en) | Anti-hypercholesterolemic compounds | |
| MA29647B1 (fr) | Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement | |
| MA30781B1 (fr) | Inhibiteur de kinase | |
| MA35285B1 (fr) | Indazoles | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
| WO2007120647A3 (fr) | Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MXPA06000326A (es) | Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones. | |
| WO2005062824A8 (fr) | Composes anti-hypercholesterolemie | |
| MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
| MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
| MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer | |
| TW200740760A (en) | Malonamide derivatives | |
| MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| BR0312934A (pt) | Derivados de 8-hidróxi quinolina | |
| NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| WO2007087151A3 (fr) | Méthode de traitement d'un dysfonctionnement cognitif | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| WO2006138163A3 (fr) | Composes anti-hypercholesterolemiques | |
| NO20073170L (no) | Kaspaseinhibitorer og anvendelse derav | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| NO20034301L (no) | Cyano-substituerte dihydropyrimidin forbindelser |